Danny Buitenhuis

Danny Buitenhuis is a Researcher in the Department of Hematology at Erasmus University Rotterdam (Erasmus MC), specializing in clinical translation of novel therapeutics for hematological malignancies with emphasis on multiple myeloma. His institutional affiliation positions him within a leading European academic medical center dedicated to oncology research and patient care.

His research program centers on optimizing treatment regimens for vulnerable patient populations, particularly:

• Mechanisms and management of multiple myeloma
• Novel agent combinations (daratumumab, ixazomib)
• Low-dose corticosteroid protocols
• Frailty assessment in cancer therapy
• Progression-free survival metrics
• Pharmacokinetics in elderly patients

Dr. Buitenhuis focuses on bridging laboratory discoveries with clinical applications through rigorous trial design, specifically developing tolerable yet effective regimens for intermediate-fit and frail patients who cannot withstand conventional intensive therapies. His work addresses critical gaps in personalized myeloma treatment where standard protocols pose unacceptable toxicity risks.

Analysis of his publication profile reveals concentrated expertise in phase 2 clinical trials evaluating targeted biologic agents, with recent work establishing evidence for ixazomib-daratumumab-low-dose dexamethasone combinations. This research demonstrates consistent methodology in dose optimization studies with strong translational relevance to real-world oncology practice.

No scientific awards or major grant funding were documented in the source material. His collaborative approach is evident through extensive co-authorship networks involving 20+ clinicians and researchers across Dutch medical institutions, indicating active participation in multidisciplinary tumor boards and trial consortia.

Dr. Buitenhuis operates within Erasmus MC's hematology research ecosystem, contributing to the center's reputation in plasma cell disorder innovation through close integration with clinical teams at the Rotterdam cancer institute.